Shares of Mirati Therapeutics, Inc. (MRTX) are down more than 5% Monday morning after the news of Bristol Myers Squibb acquiring the company for $58 per share in cash, below Friday's closing price of $60.20.
The deal involves consideration of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash.
The aquisition adds KRAZATI, Mirati's FDA approved treatment of Non-Small Cell Lung Cancer (NSCLC), to Bristol Myers Squibb's oncology portfolio. KRAZATI is also being investigated as a combination therapy. Mirati's oncology pipeline include MRTX1133, MRTX1719, and MRTX0902, which are in early stages of studies.
MRTX is at $56.98. It has traded in the range of $27.30 - $101.30 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.